Novartis to close cell and gene therapies unit

1 September 2016

Novartis (NOVN: VX) is to close its Cell and Gene Therapies Unit in a move which will cause job losses and redeployments at the Swiss pharma giant.

The company will no longer have a separate unit conducting this research, the Basel-based company has said, but it stressed that its development plan for the oncology candidate CTL019, for relapsed/refractory (r/r) pediatric acute lymphoblastic leukemia (ALL) patients, will not be affected.

A statement from Novartis said: “Novartis is committed to the ongoing development of CAR T therapies and remains well positioned to successfully launch CTL019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK